U.S. Markets close in 3 hrs 54 mins

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.17+0.22 (+3.09%)
As of 12:04PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.95
Open7.01
Bid7.16 x 2200
Ask7.19 x 3200
Day's Range7.01 - 7.28
52 Week Range4.90 - 30.10
Volume292,810
Avg. Volume1,024,003
Market Cap182.063M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-1.63
Earnings DateAug 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.67
  • Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters
    GlobeNewswire

    Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters

    Investments expected to accelerate development timelines and reduce development expensesDURHAM, N.C., June 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the expansion of its research and development facilities in Morrisville, North Carolina. The expansion w

  • Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
    GlobeNewswire

    Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting

    Survival benefit observed in two treatment settings of previously treated non-small lung cancer patientsDURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Dr. Roger B. Cohen, MD, Professor of Medicine at the University of Pennsylvania Perelman School of Medicine, presented an overview of the latest HS-110 data at the 2021

  • HTBX: 1Q:21 Results
    Zacks Small Cap Research

    HTBX: 1Q:21 Results

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT First Quarter 2021 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported first quarter 2021 results on May 5, 2021, concurrent with the submission of Form 10-Q to the SEC. Highlights for the first quarter ending March 31, 2021 and to-date include: ➢ Appointment of William Ostrander as CFO - January 2021 ➢ Commencement of